Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.

Thierry André David Tougeron Guillaume Piessen Christelle De La FouchardièreChristophe LouvetAntoine Adenis Marine JaryChristophe TournigandThomas AparicioJérôme DesrameAstrid LièvreMarie-Line Garcia-LarnicolThomas PudlarzRomain CohenSalomé MemmiDewi VernereyJulie HenriquesJérémie H Lefevre Magali Svrcek

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

Nivolumab and ipilimumab-based neoadjuvant therapy is feasible and associated with no unexpected toxicity and a high pCR rate in patients with dMMR/MSI-H resectable gastric/GEJ adenocarcinoma.

Keyphrases

locally advanced
phase ii study
rectal cancer
squamous cell carcinoma
radiation therapy
early stage
oxidative stress
lymph node
randomized controlled trial
mesenchymal stem cells
clinical trial
open label
smoking cessation
placebo controlled
genetic diversity
double blind
wild type